OR WAIT 15 SECS
The company will present results of a three-year study on its MenaQ7 vitamin K2 at VitaFoods in Geneva.
NattoPharma ASA (Lysaker, Norway), a supplier of vitamin K2 ingredients, will present results of a three-year study on its MenaQ7 vitamin K2 at next week’s VitaFoods show in Geneva.
Vitamin K2 remains an up-and-coming ingredient for bone and vascular health. As a nutrient that helps deliver calcium from blood to bones, vitamin K2 could be well suited for calcium and vitamin D formulas.
Researchers at Maastricht University in the Netherlands assigned 244 postmenopausal women to a low dose of MenaQ7 (180 mcg) or placebo for three years. While full results of the study are still under wraps, NattoPharma has stated that its ingredient was linked to several improvements in cardiovascular disease parameters-including improved pulse wave velocity (a marker of arterial stiffness)-and amount and quality of bone in subjects.
To learn more about the study while attending VitaFoods, attend a presentation with lead researcher Cees Vermeer at 11:05 on Tuesday, May 22 or visit NattoPharma at booth 1151.